Tetraphase's Broad-Spectrum Antibiotic Candidate Makes A Good Showing At ICAAC
This article was originally published in The Pink Sheet Daily
The Boston area start-up aims to offer a "franchise of antibiotics" based on its synthetic tetracycline platform.
You may also be interested in...
Antibiotic resistance has become a key market opportunity, but Big Pharma is poorly positioned to take advantage. Having all but abandoned antibiotic drug development at least a decade ago to smaller companies able to take on the risk, major drugmakers now look to those firms as a resource to revive their pipelines. But there may not be much to choose from.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.